Hydroxydiosmin shows a broad application prospect in the pharmaceutical field, especially in anti-cancer treatment and anti-inflammatory and anti-oxidation. With in-depth clinical trials and continuous technological innovation, the market scale of hydroxydiosmin is expected to continue to expand, bringing benefits to more patients.
1. Core application areas
Anti-cancer treatment
Mechanism of action:
Inhibit tumor proliferation: induce apoptosis of tumor cells by regulating cell cycle proteins (e.g. Cyclin D1) and pro-apoptotic proteins (e.g. Bax).
Anti-angiogenesis: down-regulate the expression of vascular endothelial growth factor (VEGF) to block tumor neovascularization.
Immunomodulation: Enhance the activity of natural killer cells (NK cells) to improve the body’s ability to clear cancer cells.
Clinical application:
Gastrointestinal tumors: as an adjuvant therapy drug, combined with chemotherapy can enhance the efficacy and reduce side effects.
Colorectal cancer: significantly improve the prognosis and increase the 5-year survival rate of patients.
Other cancers: showed potential application value in lung cancer and breast cancer, further clinical trials are needed to verify.
Antioxidant and anti-inflammatory
Antioxidant mechanism: scavenging free radicals (e.g. superoxide anion, hydroxyl radical), protecting cells from oxidative stress damage.
Anti-inflammatory effects: inhibit the release of inflammatory factors (e.g., TNF-α, IL-6) to alleviate chronic inflammatory diseases (e.g., arthritis, inflammatory bowel disease).
Vascular protection
Improve venous function: Enhance venous tone, promote lymphatic return, reduce lower limb edema and pain.
Treatment of venous ulcers: Micronized deoxynivalenol (trade name: Getachem®) dose-dependently improves venous leakage and maintains endothelial integrity.
2. Clinical Trial Breakthroughs
Post-operative recovery
After Total Knee Arthroplasty (TKA): A national multi-center RCT confirmed that Diosmin significantly reduced postoperative lower limb swelling and pain, and shortened the recovery cycle.
Mechanism support: It works by protecting microcirculation and inhibiting the release of inflammatory mediators (e.g. CRP, IL-6).
Venous Ulcer Treatment
Dose-dependent study: The 40 mg/kg/day dose group (clinically equivalent to 4 tablets/day) was superior to the low dose group in maintaining venous integrity, improving muscle damage, and had a favorable safety profile.